Prostate cancer

This article aims to summarize the current knowledge of prostate cancer and treatment options available.
Source: Surgery (Oxford) - Category: Surgery Source Type: research

Related Links:

Publication date: Available online 13 September 2019Source: European UrologyAuthor(s): Antonio Alcaraz
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Metastatic Castration-Resistant Prostate Cancer (mCRPC) Interventions:   Drug: AZD4635;   Drug: Oleclumab;   Drug: Durvalumab Sponsor:   AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionBoth the IVIM and DKI models are beneficial to predict GS of PCa and indirectly predict its aggressiveness, and they have a comparable diagnostic performance with each other as well as ADC.
Source: Abdominal Imaging - Category: Radiology Source Type: research
Authors: Marra G, Dell'oglio P, Baghdadi M, Cathelineau X, Sanchez-Salas R, EvaluatioN of HIFU Hemiablation and short term AndrogeN deprivation therapy Combination to Enhance prostate cancer control (ENHANCE) study investigators Abstract FT for localized PCa is emerging to reduce adverse effects of radical treatments, while maintaining comparable oncological outcomes. However, an area for improvement still exists and a gap in cancer control needs to be filled by complementing the with additional forms of treatment to minimize failures. Part of the recurrences/persistences after FT may be related to PCa microenviron...
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
Publication date: December 2019Source: Journal of Health Economics, Volume 68Author(s): Sung-Hee Jeon, R. Vincent PohlAbstractInnovations in cancer treatment have lowered mortality, but little is known about their economic benefits. We assess the effect of two decades of improvement in cancer treatment options on the labor market outcomes of breast and prostate cancer patients. In addition, we compare this effect across cancer patients with different levels of educational attainment. We estimate the effect of medical innovation on cancer patients’ labor market outcomes employing tax return and cancer registry data fr...
Source: Journal of Health Economics - Category: Health Management Source Type: research
We report that RhoBTB1 depletion increases prostate cancer cell invasion and induces elongation in Matrigel, a phenotype similar to that induced by depletion of ROCK1 and ROCK2. We demonstrate that RhoBTB1 associates with ROCK1 and ROCK2 and its association with ROCK1 is via its Rho domain. The Rho domain binds to the coiled-coil region of ROCK1 close to its kinase domain. We identify two amino acids within the Rho domain that alter RhoBTB1 association with ROCK1. RhoBTB1 is a substrate for ROCK1, and mutation of putative phosphorylation sites reduces its association with Cullin3, a scaffold for ubiquitin ligases. We propo...
Source: Biochemical Journal - Category: Biochemistry Authors: Tags: Research Articles Source Type: research
BOSTON (CBS) – Some good news about mushrooms. A new study published in the International Journal of Cancer finds that the fungi may help prevent prostate cancer in men. Researchers looked at more than 30,000 middle aged and elderly Japanese men who were followed for more than 13 years. They found that those who ate mushrooms once or twice a week had an 8-percent lower risk of prostate cancer and if they ate mushrooms three or more times a week, they had a 17-percent lower risk. It’s unclear which type of mushrooms may be beneficial or why mushrooms may have a protective effect, but this study may lead to furth...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Healthwatch Dr. Mallika Marshall Prostate Cancer Source Type: news
ConclusionSRT to the macroscopic recurrence identified by mpMRI is a feasible and well-tolerated option. In this study, there were no differences in bRFS between MRI-positive and MRI-negative patients, indicating effective targeting of MRI-positive lesions.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
The American Cancer Society estimates there will be nearly 175,000 new prostate cancer cases in the United States this year and over 31,000 deaths. One in nine men will be diagnosed with prostate cancer in their lifetime.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Condition:   Prostate Cancer Interventions:   Drug: Capivasertib;   Drug: Enzalutamide;   Drug: Abiraterone Sponsors:   AstraZeneca;   Parexel Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Prostate Cancer | Surgery